Press Releases

January 25, 2007

Gilead Sciences Announces Senior Management Promotion

FOSTER CITY, Calif.--(BUSINESS WIRE)--Jan. 25, 2007--Gilead Sciences, Inc. (Nasdaq:GILD) announced today the promotion of Jim Meyers to Senior Vice President, Commercial Operations, North America. Mr. Meyers is responsible for the company's commercial organization in North America, including U.S. and Canadian sales, marketing and commercial operations, reporting to Kevin Young, Gilead's Executive Vice President, Commercial Operations. In this new role, Mr. Meyers will join Gilead's Executive Committee.

Mr. Meyers joined Gilead in 1996 as a regional sales director and relocated to the company's headquarters in 1997 to head the HIV marketing team. In 2001 he was named Senior Director of U.S. Sales, overseeing the expansion of the company's field sales organization in advance of the launch of Gilead's first product for the treatment of HIV. He was promoted to Vice President in 2002, and appointed to the position of Vice President of the U.S. Commercial organization in 2004. Prior to joining Gilead, Mr. Meyers held positions of increasing responsibility in sales, training, marketing and management with Zeneca Pharmaceuticals and Astra USA. He is a graduate of Boston College, with a Bachelor's degree in economics.

"Over the last ten years, Jim has contributed significantly to the growth and success of Gilead's commercial organization," said Mr. Young. "As we extend our commercial presence and expand into new therapeutic areas, Jim's leadership and depth of expertise will ensure we continue to meet our aggressive goals and deliver new medications to those patients most in need."

About Gilead Sciences

Gilead Sciences is a biopharmaceutical company that discovers, develops and commercializes innovative therapeutics in areas of unmet medical need. The company's mission is to advance the care of patients suffering from life-threatening diseases worldwide. Headquartered in Foster City, California, Gilead has operations in North America, Europe and Australia.

For more information on Gilead, please call the Gilead Public Affairs Department at 1-800-GILEAD-5 (1-800-445-3235) or visit www.gilead.com.

CONTACT: Gilead Sciences, Inc.
Susan Hubbard, 650-522-5715 (Investors)
Amy Flood, 650-522-5643 (Media)
SOURCE: Gilead Sciences, Inc.